中
Home
About TUL
Group Introduction
Executive Directors
Subsidiaries
Contact Us
Innovation in R&D
R&D Pipeline
R&D Platform
R&D Updates
News
TUL Highlights
Product Center
Finished Products
Comprehensive Health Products
APIs and Intermediates
Animal protection products
Empty capsule
Medical device
Cosmetic Peptide Series
Sustainability
Enhancing Governance
Normalizing Healthiness
Brand Building
People-Oriented
Green Development
ESG Reports
ESG News
Investor Relations
News
TUL Highlights
2026-09-07
UBT251 INJECTION COMPLETED FIRST PARTICIPANT DOSING IN PHASE III CLINICAL STUDY FOR OVERWEIGHT OR OBESITY IN CHINA
Learn More
2026-09-07
Significant Progress in Innovative Drug R&D and Continued Globalization Efforts Profit Attributable to Owners of the Company Reached Approximately RMB347.6 Million
Learn More
2026-08-12
FDA APPROVAL OF IND FOR THE GROUP’S PRODUCT UBT48128 TABLETS
Learn More
2026-07-15
APPROVAL FOR MARKETING OF THE GROUP’S PRODUCT SODIUM HYALURONATE EYE DROPS WITH NEW SPECIFICATION
Learn More
2026-07-03
APPROVAL FOR MARKETING OF THE GROUP’S PRODUCT TADALAFIL TABLETS
Learn More
All News
Select Year
2026
2025
2024
TUL’s UBT251 Injection Receives Clinical Trial Approval for New Indication
2025-01-22
The United Animal Healthcare (Inner Mongolia) Co., Ltd. Receives Class II New Veterinary Drug Certificates
2025-01-15
TUL Wins the “Best ESG Award” and the “Most Creative Corporate Communication Award”
2025-01-09
First batch in Guangdong! Three varieties including TUL’s liraglutide injection were approved as pilot products for segmented production
2025-01-02
TUL Makes Its Debut at CPHI Middle East
2024-12-13
TUL Receives the Title of “Most Valuable Pharmaceutical and Medical Company”
2024-12-12
TUL’s Mupirocin Ointment Receives Marketing Approval
2024-12-12
Zhuhai United Laboratories Co., Ltd. Passes Online GMP Inspection by Mexican Authorities
2024-12-12
TUL’s Sterile Amoxicillin Sodium Bulk Medicine Obtains CEP Certificate
2024-12-02
Prev
1
...
10
11
12
13
14
...
17
Next
WeChat
Official
Account
To Top